← Back to guidelines
Cardiology953 papers

Platelet dysfunction caused by aspirin

Last edited: 4/15/2026

Overview

Aspirin-induced platelet dysfunction results from irreversible inhibition of cyclooxygenase-1 (COX-1), leading to impaired platelet aggregation and increased bleeding risk 1.

Diagnosis

  • Platelet function tests (e.g., VerifyNow Aspirin Test, light transmission aggregometry) can confirm aspirin effect 1.
  • Bleeding time prolongation is a non-specific marker but may indicate significant platelet dysfunction 1.
  • Management

  • No specific antidote for aspirin-induced platelet dysfunction; focus on minimizing bleeding risk 1.
  • Consider dose reduction or alternative antiplatelet agents if bleeding complications arise 1.
  • Special Populations

  • Renal Function: Adjust aspirin dosing based on renal function to mitigate bleeding risk 1.
  • Elderly: Increased susceptibility to bleeding; careful monitoring and dose adjustment recommended 1.
  • Key Recommendations

  • Monitor platelet function tests in patients on aspirin to assess efficacy and bleeding risk (Evidence: Moderate 1).
  • Adjust aspirin dose or consider alternative antiplatelet therapies in patients with significant bleeding complications (Evidence: Expert opinion 1).
  • Account for renal function when prescribing aspirin to elderly patients to reduce bleeding risk (Evidence: Expert opinion 1).
  • References

    1 Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). European heart journal. Cardiovascular pharmacotherapy 2017. link 2 Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use?. Hematology. American Society of Hematology. Education Program 2012. link

    Original source

    1. [1]
      Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA).Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P European heart journal. Cardiovascular pharmacotherapy (2017)
    2. [2]
      New oral anticoagulants: which one should my patient use?Weitz JI, Gross PL Hematology. American Society of Hematology. Education Program (2012)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG